Motivating Structured walking Activity in people with Intermittent Claudication (MOSAIC): protocol for a randomised controlled trial of a physiotherapist-led, behavioural change intervention versus usual care in adults with intermittent claudication. Issue 8 (24th August 2019)

• Record Type: Journal Article
• Authors: Bearne, Lindsay; Galea Holmes, Melissa; Bieles, Julie; Eddy, Saskia; Fisher, Graham; Modarai, Bijan; Patel, Sanjay; Peacock, Janet L; Sackley, Catherine; Volkmer, Brittannia; Weinman, John
• Is Part Of: BMJ open. Volume 9:Issue 8(2019)
• Publication Date: 2019-08-24
• Subjects: peripheral arterial disease -- walking -- behaviour change -- physiotherapy -- intermittent claudication; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2019-030002
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Walking exercise is a recommended but underused treatment for intermittent claudication caused by peripheral arterial disease (PAD). Addressing the factors that influence walking exercise may increase patient uptake of and adherence to recommended walking. The primary aim of this randomised controlled trial (RCT) is to evaluate the efficacy of a physiotherapist-led behavioural change intervention on walking ability in adults with intermittent claudication (MOtivating Structured walking Activity in people with Intermittent Claudication (MOSAIC)) in comparison with usual care. Methods and analysis: The MOSAIC trial is a two-arm, parallel-group, single-blind RCT. 192 adults will be recruited from six National Health Service Hospital Trusts. Inclusion criteria are: aged ≥50 years, PAD (Ankle Brachial Pressure Index ≤0.90, radiographic evidence or clinician report) and intermittent claudication (San Diego Claudication Questionnaire), being able and willing to participate and provide informed consent. The primary outcome is walking ability (6 min walking distance) at 3 months. Outcomes will be obtained at baseline, 3 and 6 months by an assessor blind to group allocation. Participants will be individually randomised (n=96/group, stratified by centre) to receive either MOSAIC or usual care by an independent randomisation service. Estimates of treatment effects will use an intention-to-treat framework implemented using multiple regression adjusted for baseline values and centre. Ethics and dissemination: This trial has full ethical approval (London—Bloomsbury Research Ethics Committee (17/LO/0568)). It will be disseminated via patient forums, peer-reviewed publications and conference presentations. Trial registration number: ISRCTN14501418